While there are important similarities, the U.S. Senate and the House of Representatives have taken different approaches to several matters in their respective tax reform proposals, including the tax credit for clinical studies of orphan drugs, which the Senate bill would cut substantially while the House bill would eliminate that tax credit altogether.